Lipoprotein(a): An underestimated inflammatory mastermind

Area of Science:

• Biochemistry and Molecular Biology
• Cardiology and Cardiovascular Research
• Immunology and Inflammation

Background:

• Lipoprotein(a) [Lp(a)] is an established independent and causal risk factor for cardiovascular disease.
• Elevated Lp(a) levels (>125 nmol/L) are associated with increased arterial wall inflammation and leukocyte recruitment.
• Lp(a) plays a key role in the initiation of aortic valve stenosis and systemic inflammation.

Purpose of the Study:

• To review the cellular and molecular pathways through which Lp(a) contributes to atherosclerosis.
• To elucidate the role of Lp(a) in the pathogenesis of aortic valve stenosis.
• To explore the connection between Lp(a) and systemic inflammation, including the acute phase response.

Main Methods:

• Review of existing literature on Lp(a) and its role in cardiovascular disease.
• Analysis of cellular mechanisms involving oxidized phospholipids, endothelium, monocytes, and valve interstitial cells.
• Examination of the relationship between Lp(a) and inflammatory mediators like interleukin-6 (IL-6).

Main Results:

• Lp(a)-carried oxidized phospholipids activate endothelium, recruit monocytes, and promote leukocyte migration, driving atherosclerosis.
• Lp(a) induces osteoblastic differentiation or apoptosis in aortic valve interstitial cells, initiating calcification.
• Lp(a) is linked to systemic inflammation, with the LPA gene containing IL-6 response elements.

Conclusions:

• Lp(a) acts as a central inflammatory mediator in cardiovascular disease pathogenesis.
• Understanding Lp(a)'s multifaceted roles is crucial for developing targeted therapies.
• Lp(a) is a significant contributor to atherosclerosis, aortic valve stenosis, and systemic inflammatory responses.